Overview

Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia

Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term efficacy and safety profile of tosedostat in elderly patients suffering from refractory or relapsed Acute Myeloid Leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Chroma Therapeutics
Treatments:
Tosedostat